- KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
- 23 November 2015: Opening statement of Asia and the Pacific Group at Tenth Session of WIPO Advisory Committee on Enforcement
- US ITC notice for public comment, Jan 13, 2016 hearing, and Commission report on the TransPacific Partnership Agreement (TPP)
- My testimony this morning at the US ITC hearing on "Economic Impact of Trade Agreements"
- Seminars on Drug Pricing: Part 5 Kevin Outterson, Antibiotic Delinkage
- Tentative witness list for USITC hearing on Economic Impact of Trade Agreements
- Dr. Margaret Chan: TPP may "close access to affordable medicines"
- US Chamber of Commerce lauds USPTO for securing a time-bound LDC waiver for pharmaceutical products
- Economist Bhaven Sampat presents research on role of government funding in drug development
- Joint NGO Statement on TRIPS Council Decision On Extension of the Transition Period Concerning Pharmaceutical Products
May 21, 2015- Agenda for KEI/KEI Europe panel on Compulsory licensing of patents on drugs, vaccines and diagnostic testsSubmitted by thiru on 20. May 2015 - 9:36
Compulsory licensing of patents on drugs, vaccines and diagnostic tests
Knowledge Ecology International (KEI) and Knowledge Ecology International Europe (KEI Europe):
DATE: Thursday, 21 May 2015
VENUE: Kofi Annan Room, UNAIDS, Avenue Appia 20
- Ellen 't Hoen, Medicines, Law and Policy
WHA68: Greek Minister of Health - Panagiotis Kouroumplis - calls for de-linkage of R&D from the price of health technologiesSubmitted by thiru on 18. May 2015 - 16:15
On Monday, 18 May 2015, the Greek Minister of Health, Panagiotis Kouroumplis, delivered the following speech at the World Health Assembly in Geneva, explicitly calling for the de-linkage of the "cost of R&D from the final price of medicines" while highlighting the deleterious effects of austerity measures eroding public health systems, counter to the theme of WHA68, "Resilient Health Systems".
Here is his speech in full:
Madam Director General, dear colleagues, excellencies, ladies and gentlemen
This is a briefing note prepared for TPP negotiators, addressing a single but important issue, the standards for issuing compulsory licenses in the TPP.
Attached is the text of a letter sent by Senator Bernie Sanders to Robert A. McDonald, the Secretary, U.S. Department of Veterans Affairs, asking the Secretary "to use your authority as Secretary of Veterans Affairs to break the patents on Hepatitis C medications for the treatment of veterans suffering with the disease."
UACT Comments to DHHS on WHA: Agenda Item 13.4 Assessment of Progress in Prevention & Control of NCDsSubmitted by Manon Ress on 8. May 2015 - 14:35
To prepare for the upcoming 68th World Health Assembly (WHA), the U.S. Department of Health & Human Services held a Stakeholder Listening Session on Friday, May 8, 2015, from 10:30am - 12pm in the HHS Humphrey Building - 200 Independence Ave, SW, Washington, DC 20201. All Agenda items for the upcoming WHA are here:
KEI Comments to DHHS on WHA Agenda 17.5 (Global Strategy and Plan of Action on Public Health, Innovation and IP)Submitted by KEI Staff on 8. May 2015 - 9:58
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here.
KEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and DevelopmentSubmitted by James Love on 8. May 2015 - 9:47
Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34
My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.
I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.
We have suggestions for some changes in the discussion, to move things forward.
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here:
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
WHO Expert Committtee adds trastuzumab, imatinib, daclatasvir, sofosbuvir, bedaquiline and delaminid to EMLSubmitted by thiru on 8. May 2015 - 2:34
On Friday, 8 May 2015, the World Health Organization (WHO) unveiled its 19th WHO Model of Essential Medicines (April 2015).
With respect to cancer drugs (Section 8.2, Cytoxic and Adjuvant Medicines), the Executive Summary noted that the Committee added 16 new medicines.
WHO donors in 2014 (US, Gates Foundation, UK, GAVI and Canada): Setting the agenda for global public health?Submitted by thiru on 7. May 2015 - 4:46
In preparation for the 68th World Health Assembly, to be convened in Geneva from 18 May 2015 to 26 May 2015, the World Health Organization (WHO) prepared a document (A68/INF./1, 1 May 2015), entitled "Annex to the Financial Report for the year ended 31 December 2014, Voluntary contributions by fund and by contributor).
On May 5, 2015, KEI sent a letter to the USPTO regarding the implementation of the Beijing Treaty on Audiovisual Performances. The letter focuses on concerns that KEI and others have expressed that a treaty implementation by amendment of 17 U.S. Code § 1101, regarding the "Unauthorized fixation and trafficking in sound recordings and music videos," creates problems, because the statute involves a right that is perpetual and not subject to normal copyright exceptions.
NIH refuses to give information about principals in company seeking exclusive license to HCV patentsSubmitted by KEI Staff on 5. May 2015 - 10:24
The NIH provided these responses to four questions about the HCV drug patent license it is considering.
Every year USTR issues a list of countries targeted to be subjected to trade pressures over their policies on intellectual property rights. This year's list was published on April 30, 2015. KEI has a copy of every version of the Special 301 list here: http://www.keionline.org/ustr/special301
USTR describes the list as follows:
The Special 301 Process
Today, KEI hosted the first talk in a series of seminars on drug pricing. The seminar, conducted via video conference, focused on the Canadian approach to drug pricing. Each seminar in the series is intended to contribute to the discussion on drug pricing and how we can improve affordability and access to medicines. Paul Grootendorst began with a presentation (the slides are available here), before opening up the discussion to questions from those participating in the video conference.